CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. TOP PLAYER POSITIONING/MARKET SHARE ANALYSIS, 2016
3.4. MARKET DYNAMICS
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities

CHAPTER 4 MYCOLOGICAL TESTING MARKET, BY TECHNOLOGY

4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. ELISA
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast by region
4.2.3. Market size and forecast by country
4.3. RAPID TESTS
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast by region
4.3.3. Market size and forecast by country
4.4. ELISPOT
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast by region
4.4.3. Market size and forecast by country
4.5. POLYMERASE CHAIN REACTION (PCR)
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast by region
4.5.3. Market size and forecast by country

CHAPTER 5 MYCOLOGICAL TESTING MARKET, BY END USER

5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. HOSPITALS
5.2.1. Market size and forecast by region
5.2.2. Market size and forecast by country
5.3. CLINICAL LABORATORIES
5.3.1. Market size and forecast by region
5.3.2. Market size and forecast by country
5.4. RESEARCH CENTERS
5.4.1. Market size and forecast by region
5.4.2. Market size and forecast by country
5.5. OTHERS
5.5.1. Market size and forecast by region
5.5.2. Market size and forecast by country

CHAPTER 6 MYCOLOGICAL TESTING MARKET, BY REGION

6.1. OVERVIEW
6.2. NORTH AMERICA
6.2.1. Key market trends, growth factors and opportunities
6.2.2. North America mycological testing market, by country
6.2.2.1. U.S. mycological testing market
6.2.2.1.1. U.S. market, by technology
6.2.2.1.2. U.S. market, by end user
6.2.2.2. Canada mycological testing market
6.2.2.2.1. Canada market, by technology
6.2.2.2.2. Canada market, by end user
6.2.2.3. Mexico mycological testing market
6.2.2.3.1. Mexico market, by technology
6.2.2.3.2. Mexico market, by end user
6.2.3. North America mycological testing market, by technology
6.2.4. North America mycological testing market, by end user
6.3. EUROPE
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Europe Mycological testing market, by country
6.3.2.1. Germany mycological testing market
6.3.2.1.1. Germany market, by technology
6.3.2.1.2. Germany market, by end user
6.3.2.2. France mycological testing market
6.3.2.2.1. France market, by technology
6.3.2.2.2. France market, by end user
6.3.2.3. UK mycological testing market
6.3.2.3.1. UK market, by technology
6.3.2.3.2. UK market, by end user
6.3.2.4. Italy mycological testing market
6.3.2.4.1. Italy market, by technology
6.3.2.4.2. Italy market, by end user
6.3.2.5. Spain mycological testing market
6.3.2.5.1. Spain market, by technology
6.3.2.5.2. Spain market, by end user
6.3.2.6. Rest of Europe mycological testing market
6.3.2.6.1. Rest of Europe market, by technology
6.3.2.6.2. Rest of Europe market, by end user
6.3.3. Europe mycological testing market, by technology
6.3.4. Europe mycological testing market, by end user
6.4. ASIA-PACIFIC
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Asia-Pacific Mycological testing market, by country
6.4.2.1. Japan mycological testing market
6.4.2.1.1. Japan market, by technology
6.4.2.1.2. Japan market, by end user
6.4.2.2. China mycological testing market
6.4.2.2.1. China market, by technology
6.4.2.2.2. China market, by end user
6.4.2.3. Australia mycological testing market
6.4.2.3.1. Australia market, by technology
6.4.2.3.2. Australia market, by end user
6.4.2.4. India mycological testing market
6.4.2.4.1. India market, by technology
6.4.2.4.2. India market, by end user
6.4.2.5. South Korea mycological testing market
6.4.2.5.1. South Korea market, by technology
6.4.2.5.2. South Korea market, by end user
6.4.2.6. Rest of Asia-Pacific mycological testing market
6.4.2.6.1. Rest of Asia-Pacific market, by technology
6.4.2.6.2. Rest of Asia-Pacific market, by end user
6.4.3. Asia-Pacific mycological testing market, by technology
6.4.4. Asia-Pacific mycological testing market, by end user
6.5. LAMEA
6.5.1. Key market trends, growth factors and opportunities
6.5.2. LAMEA Mycological testing market, by country
6.5.2.1. Brazil mycological testing market
6.5.2.1.1. Brazil market, by technology
6.5.2.1.2. Brazil market, by end user
6.5.2.2. Saudi Arabia mycological testing market
6.5.2.2.1. Saudi Arabia market, by technology
6.5.2.2.2. Saudi Arabia market, by end user
6.5.2.3. South Africa mycological testing market
6.5.2.3.1. South Africa market, by technology
6.5.2.3.2. South Africa market, by end user
6.5.2.4. Rest of LAMEA mycological testing market
6.5.2.4.1. Rest of LAMEA market, by technology
6.5.2.4.2. Rest of LAMEA market, by end user
6.5.3. LAMEA mycological testing market, by technology
6.5.4. LAMEA mycological testing market, by end user

CHAPTER 7 COMPANY PROFILES

7.1. F. HOFFMANN-LA ROCHE LTD
7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments
7.2. ABBOTT LABORATORIES, INC.
7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments
7.3. SIEMENS AG
7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments
7.4. BECKMAN COULTER, INC.
7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments
7.5. ORTHO-CLINICAL DIAGNOSTICS, INC.
7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments
7.6. BIOMÉRIEUX SA
7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments
7.7. ELITECHGROUP
7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments
7.8. MIRAVISTA DIAGNOSTICS
7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments
7.9. ALS
7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments
7.10. BCN RESEARCH LABORATORIES, INC.
7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments